Mirati Therapeutics Культура компании

Mr. Jamie A. Donadio,PhD has been the Chief Financial Officer and Senior Vice President at Mirati Therapeutics, Inc. since March 21, 2016 and served as its Vice President of Finance from March 18, 2013 to March 21, 2016 and served as its Principal Accounting Officer. Prior to joining Mirati, Mr. Donadio was at Amylin Pharmaceuticals, Inc. from April 2001 to January 2013. From November 2011 to January 2013, he served as Senior Director of Finance at Amylin Pharmaceuticals, Inc. From December 2010 to November 2011, he served as Director of Corporate Financial Planning and Analysis at Amylin Pharmaceuticals, Inc. from March 2007 to December 2010 he served as Director of SEC Reporting and from April 2001 to March 2007, he held various corporate accounting roles at Amylin Pharmaceuticals, Inc. From December 2000 to April 2001, he was senior accountant at Novatel Wireless, Inc. From August 1997 to December 2000, he was with Ernst & Young LLP, last serving as an audit senior. Mr. Donadio holds a B.S. in Accounting from Babson College and is a certified public account (inactive) in the State of California.

Dr. James Christensen, Ph.D. has been Chief Scientific Officer of Mirati Therapeutics, Inc. since January 31, 2014. Dr. Christensen has been Senior Vice President at Mirati Therapeutics, Inc. since January 2014. Dr. Christensen served as Vice President of Research at Mirati Therapeutics, Inc. from June 2013 to January 2014. Dr. Christensen served as the Senior Director of Oncology Precision Medicine in the Oncology Research Unit at Pfizer. He joined Pfizer in 2003 and his responsibilities there included leading nonclinical research efforts for oncology programs including sunitinib malate research activities and leading the nonclinical and translational biology efforts for other research and development programs including crizotinib. He participated as a Member of the Pfizer Cancer Research or Oncology Research Unit leadership team from 2005 to 2013. Prior to 2003, he was at SUGEN/Pharmacia as a Group Leader on the Preclinical Research and Exploratory Development team, where he was responsible for leadership of Met and erbB family preclinical development programs and aspects of research and development for Sutent. He initiated his industry experience at Warner Lambert/Parke-Davis with research focus in RTK biology and RTK pathway biomarker development in the oncology therapeutic area. He has authored or co-authored over 100 peer-reviewed research articles in scientific journals including Science, Nature, Cancer Cell, New England Journal of Medicine and others. In addition, he participates on the editorial boards for Cancer Research and Molecular Cancer Therapeutics. Dr. Christensen received his Ph.D. degree focusing in Molecular Pharmacology from North Carolina State University with dissertation research directed toward characterization of mechanisms of apoptosis dysregulation during the process of carcinogenesis.

Dr. Isan Chen, M.D., has been Chief Medical & Development Officer and Executive Vice President at Mirati Therapeutics, Inc. since September 4, 2013. Dr. Chen is board certified in Internal medicine, hematology and medical oncology with more than 15 years of experience in oncology and clinical trials from first-in-humans through global registrational studies. He has experience in oncology clinical development and interactions with regulatory agencies in the United States and Europe. Mr. Chen served as the Chief Medical Officer of Aragon Pharmaceuticals, Inc., which was acquired by Johnson & Johnson. Previously he served as Vice-President, Genitourinary Tumor Strategy Leader for Pfizer Oncology. Before joining Pfizer, Dr. Chen practiced medicine as a staff physician at City of Hope Medical Center and later as an assistant professor at the University of Texas, M.D. Anderson Cancer Center. He was the clinical lead for Sutent, a multiple kinase inhibitor, for the treatment of RCC, an indication in which the drug secured FDA approval in 2006. He was also the clinical lead for the Phase 1 studies of crizotinib and CDK 4/6 inhibitor palbociclib. He served as a faculty member in the Department of Genitourinary Medical Oncology at the University of Texas, MD Anderson Cancer Center. He completed his hematology-oncology fellowship at University of California, San Diego.

Dr. Rodney W. Lappe, Ph.D. has been the Executive Chairman of Mirati Therapeutics, Inc. since July 2013 and its Director since June 27, 2012. Since January 2012, Dr. Lappe has served as the Senior Vice President of Tavistock Life Sciences. He served as the Chief Scientific Officer of CovX Research LLC. Dr. Lappe joined CovX in January 2004. From January 2004 to December 2011, he was Group Senior Vice President, Pfizer Worldwide Research and Development at CovX Research LLC. He joined Pfizer with the CovX acquisition in 2008. Dr. Lappe has been responsible for the advancement of large portfolios of drug discovery projects and has promoted multiple therapeutic candidates through pre-clinical and clinical development. From 2000 to 2002, Dr. Lappe, he served as Vice President for cardiovascular and metabolic diseases at Pharmacia where he contributed to the registration of Inspra???. He was also the site leader for Pharmacia in St. Louis. He has been a Director of MethylGene Inc., since June 27, 2012. He served as a Director of Neuren Pharmaceuticals Ltd. until April 2, 2004. Prior to joining Pharmacia, he held positions of increasing responsibility with Wyeth Laboratories, Rorer Central Researh, CIBA Geigy Pharmaceuticals and Searle Pharmaceuticals. He has 23 years of drug discovery experience in the pharmaceutical industry. Dr. Lappe has experience managing pharmaceutical and biotech companies. He has a strong understanding of pharmacology, a clear strategic scientific vision and extensive experience in international drug discovery collaborations. Dr. Lappe received his PhD in Pharmacology from Indiana University and his BA from Blackburn College.

Chris LeMasters serves as the Chief Business Officer for Mirati Therapeutics. Chris started at Mirati Therapeutics in October of 2016. Chris is based in the Greater San Diego Area.

James Christensen serves as the CSO and Executive Vice President Research of Mirati Therapeutics. James started at Mirati Therapeutics in July of 2013. James currently resides in the Greater San Diego Area.

Jamie Donadio serves as the Senior Vice President and Chief Financial Officer of Mirati Therapeutics. Jamie started at Mirati Therapeutics in March of 2016. Jamie currently resides in the Greater San Diego Area.